Epigenetic Alzheimer's Drug FLAV-27 Reverses Memory Decline in Mice

Researchers report FLAV-27, a G9a/EHMT2 inhibitor, epigenetically reprograms neuronal gene expression to combat Alzheimer's pathology; in cell cultures, nematodes, and mice it reduced disease features and restored memory and synaptic function, suggesting a broader upstream approach beyond amyloid and tau. The compound has not yet been tested in humans and would require extensive safety and regulatory steps before trials.